Black Diamond Therapeutics Inc expected to post a loss of 61 cents a share - Earnings Preview

Black Diamond Therapeutics

05/05/2023 15:51

* Black Diamond Therapeutics Inc  BDTX.OQ   BDTX.O  is
expected
to show no change in quarterly revenue when it reports 
results on May 9 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Black Diamond
Therapeutics Inc is for a loss of 61 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Black
Diamond
Therapeutics Inc is $4​, above​ its last closing price of $1.74.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              -0.63      -0.59     Beat    6
 Sep. 30 2022  -0.64       -0.64      -0.60     Beat    6.3
 Jun. 30 2022  -0.69       -0.68      -0.63     Beat    7.4​
 Mar. 31 2022  -0.78       -0.75      -0.70     Beat    6.8
 ​​Dec.                    -1.01      -0.71     Beat    29.9
 31 2021                                                
 Sep. 30 2021  -0.98       -0.98      -0.97     Beat    0.9​
 Jun. 30 2021  -0.87       -0.84      -0.95     Missed  -13.1
 Mar. 31 2021  -0.67       -0.68      -0.84     Missed  -23.7
 This summary was machine generated May 5 at 14:51 GMT.  All
figures in US dollars  unless otherwise stated